Bausch + Lomb (NYSE:BLCO) Price Target Raised to $17.00

Bausch + Lomb (NYSE:BLCO) had its price target upped by Wells Fargo & Company from $16.00 to $17.00 in a report issued on Friday,Benzinga reports. Wells Fargo & Company currently has an equal weight rating on the stock.

Other equities research analysts also recently issued research reports about the company. Citigroup reaffirmed a “neutral” rating on shares of Bausch + Lomb in a research report on Tuesday, October 7th. Morgan Stanley raised their price target on Bausch + Lomb from $12.00 to $13.00 and gave the stock an “equal weight” rating in a research note on Friday, August 1st. Zacks Research raised shares of Bausch + Lomb to a “hold” rating in a research note on Tuesday, August 12th. Barclays increased their price objective on shares of Bausch + Lomb from $16.00 to $17.00 and gave the stock an “equal weight” rating in a report on Friday, October 31st. Finally, HC Wainwright boosted their target price on shares of Bausch + Lomb from $16.00 to $17.00 and gave the company a “buy” rating in a report on Friday, October 31st. Four research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Bausch + Lomb currently has an average rating of “Hold” and a consensus price target of $16.58.

Bausch + Lomb Stock Performance

NYSE:BLCO opened at $15.57 on Friday. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.51 and a quick ratio of 0.98. The firm has a market cap of $5.52 billion, a PE ratio of -17.90, a P/E/G ratio of 1.52 and a beta of 0.63. The firm has a 50 day simple moving average of $15.22 and a 200-day simple moving average of $13.81. Bausch + Lomb has a 1-year low of $10.45 and a 1-year high of $20.71.

Bausch + Lomb (NYSE:BLCO) last released its earnings results on Wednesday, October 29th. The company reported $0.18 EPS for the quarter, topping the consensus estimate of $0.16 by $0.02. The firm had revenue of $1.28 billion during the quarter, compared to analysts’ expectations of $1.28 billion. Bausch + Lomb had a negative net margin of 6.13% and a positive return on equity of 2.42%. Bausch + Lomb’s revenue for the quarter was up 7.1% on a year-over-year basis. During the same period in the previous year, the company earned $0.13 EPS. Bausch + Lomb has set its FY 2025 guidance at EPS. On average, equities analysts expect that Bausch + Lomb will post 0.74 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Deutsche Bank AG purchased a new stake in Bausch + Lomb in the 1st quarter worth about $50,750,000. Alberta Investment Management Corp increased its holdings in shares of Bausch + Lomb by 8.6% in the 1st quarter. Alberta Investment Management Corp now owns 3,266,193 shares of the company’s stock valued at $47,360,000 after purchasing an additional 258,000 shares during the period. Oaktree Capital Management LP lifted its position in shares of Bausch + Lomb by 28.7% in the third quarter. Oaktree Capital Management LP now owns 3,245,439 shares of the company’s stock worth $48,909,000 after purchasing an additional 724,194 shares in the last quarter. Goldentree Asset Management LP boosted its holdings in shares of Bausch + Lomb by 14.9% during the second quarter. Goldentree Asset Management LP now owns 2,583,185 shares of the company’s stock worth $33,524,000 after purchasing an additional 334,916 shares during the period. Finally, Glenview Capital Management LLC boosted its holdings in shares of Bausch + Lomb by 210.8% during the second quarter. Glenview Capital Management LLC now owns 1,553,855 shares of the company’s stock worth $20,216,000 after purchasing an additional 1,053,855 shares during the period. 11.07% of the stock is owned by institutional investors and hedge funds.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.